Author:
Koenigs Maria B,Lefranc-Torres Armida,Bonilla-Velez Juliana,Patel Krupal B,Hayes D Neil,Glomski Krzysztof,Busse Paul M,Chan Annie W,Clark John R,Deschler Daniel G,Emerick Kevin S,Hammon Rebecca J,Wirth Lori J,Lin Derrick T,Mroz Edmund A,Faquin William C,Rocco James W
Abstract
Abstract
Background
Oropharyngeal squamous carcinoma (OPSC) continues to increase in incidence secondary to human papillomavirus (HPV) infection. Despite the good overall prognosis for these patients, treatment with chemoradiation is associated with morbidity and treatment failure. Better predictors for disease outcome are needed to guide de-intensification regimens. We hypothesized that estrogen receptor α (ERα), a prognostic biomarker in oncology with therapeutic implications, might have similar utility in OPSC.
Methods
To investigate associations among ERα and demographics, HPV status, and survival, we analyzed ERα mRNA expression of head and neck squamous carcinomas (HNSC) from The Cancer Genome Atlas (TCGA) and immunohistochemistry (IHC) of pretreatment biopsy specimens from an independent group of 215 OPSC patients subsequently treated with primary chemoradiation (OPSC-CR). Associations among variables were evaluated with Fisher exact tests and logistic regression; associations with survival were evaluated with log-rank tests and Cox proportional hazards regression.
Results
Among 515 patients in TCGA, ERα mRNA expression was highest in HPV-positive OPSC. High ERα mRNA expression was associated with improved survival among those receiving chemoradiation (hazard ratio adjusted for HPV status = 0.44, 95% confidence interval = 0.21 to 0.92). In OPSC-CR, ERα was positive by IHC in 51.6% of tumors and was associated with improved overall, disease-specific, progression-free, and relapse-free survival (log-rank tests: P < .001, P < .001, P = .002, P = .003, respectively); statistically significant associations of ERα positivity with improved survival were maintained after adjusting for clinical risk factors including HPV status.
Conclusion
In two independent cohorts, ERα is a potential biomarker for improved survival that also may represent a therapeutic target in OPSC.
Funder
National Institutes of Health
The Ohio State University and of Massachusetts Eye and Ear
Massachusetts Eye and Ear Bacardi Biobank Fund
The Ohio State University
Joan Levy Bisesi Foundation
Dana-Farber/Harvard Cancer Center
National Cancer Institute Cancer Center
NIH
Publisher
Oxford University Press (OUP)
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献